Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


A reignited debate over the cell(s) of origin for glioblastoma and its clinical implications.

Fan X, Xiong Y, Wang Y.

Front Med. 2019 Jul 16. doi: 10.1007/s11684-019-0700-1. [Epub ahead of print] Review.


Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype.

Lim DA, Cha S, Mayo MC, Chen MH, Keles E, VandenBerg S, Berger MS.

Neuro Oncol. 2007 Oct;9(4):424-9. Epub 2007 Jul 10.


Laser interstitial thermal therapy for newly diagnosed and recurrent glioblastoma.

Thomas JG, Rao G, Kew Y, Prabhu SS.

Neurosurg Focus. 2016 Oct;41(4):E12.


Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance.

Nguyen HS, Shabani S, Awad AJ, Kaushal M, Doan N.

Int J Mol Sci. 2018 Jun 14;19(6). pii: E1765. doi: 10.3390/ijms19061765. Review.


Revisit the Candidacy of Brain Cell Types as the Cell(s) of Origin for Human High-Grade Glioma.

Shao F, Liu C.

Front Mol Neurosci. 2018 Feb 21;11:48. doi: 10.3389/fnmol.2018.00048. eCollection 2018.


Decreased survival in glioblastomas is specific to contact with the ventricular-subventricular zone, not subgranular zone or corpus callosum.

Mistry AM, Dewan MC, White-Dzuro GA, Brinson PR, Weaver KD, Thompson RC, Ihrie RA, Chambless LB.

J Neurooncol. 2017 Apr;132(2):341-349. doi: 10.1007/s11060-017-2374-3. Epub 2017 Jan 10.


Glioblastoma: pathology, molecular mechanisms and markers.

Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A.

Acta Neuropathol. 2015 Jun;129(6):829-48. doi: 10.1007/s00401-015-1432-1. Epub 2015 May 6. Review.


Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.


Cytomegalovirus infection induces a stem cell phenotype in human primary glioblastoma cells: prognostic significance and biological impact.

Fornara O, Bartek J Jr, Rahbar A, Odeberg J, Khan Z, Peredo I, Hamerlik P, Bartek J, Stragliotto G, Landázuri N, Söderberg-Nauclér C.

Cell Death Differ. 2016 Feb;23(2):261-9. doi: 10.1038/cdd.2015.91. Epub 2015 Jul 3.


Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.

Niranjan A, Kano H, Iyer A, Kondziolka D, Flickinger JC, Lunsford LD.

J Neurosurg. 2015 Apr;122(4):757-65. doi: 10.3171/2014.11.JNS13295. Epub 2015 Jan 16.


Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.

Zhang G, Huang S, Zhang J, Wu Z, Lin S, Wang Y.

J Neurooncol. 2016 Apr;127(2):355-62. doi: 10.1007/s11060-015-2046-0. Epub 2016 Jan 2.


Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modrusan Z, Jiang Z, Aldape KD, Mischel PS, Liau LM, Escovedo CJ, Chen W, Nghiemphu PL, James CD, Prados MD, Westphal M, Lamszus K, Cloughesy T, Phillips HS.

J Clin Oncol. 2011 Dec 1;29(34):4482-90. doi: 10.1200/JCO.2010.33.8715. Epub 2011 Oct 24.


Human glioblastoma arises from subventricular zone cells with low-level driver mutations.

Lee JH, Lee JE, Kahng JY, Kim SH, Park JS, Yoon SJ, Um JY, Kim WK, Lee JK, Park J, Kim EH, Lee JH, Lee JH, Chung WS, Ju YS, Park SH, Chang JH, Kang SG, Lee JH.

Nature. 2018 Aug;560(7717):243-247. doi: 10.1038/s41586-018-0389-3. Epub 2018 Aug 1.


Glioblastoma Cell Malignancy and Drug Sensitivity Are Affected by the Cell of Origin.

Jiang Y, Marinescu VD, Xie Y, Jarvius M, Maturi NP, Haglund C, Olofsson S, Lindberg N, Olofsson T, Leijonmarck C, Hesselager G, Alafuzoff I, Fryknäs M, Larsson R, Nelander S, Uhrbom L.

Cell Rep. 2017 Jan 24;18(4):977-990. doi: 10.1016/j.celrep.2017.01.003. Erratum in: Cell Rep. 2017 May 2;19(5):1080-1081.


Interactions between tumor-associated macrophages and tumor cells in glioblastoma: unraveling promising targeted therapies.

Morisse MC, Jouannet S, Dominguez-Villar M, Sanson M, Idbaih A.

Expert Rev Neurother. 2018 Sep;18(9):729-737. doi: 10.1080/14737175.2018.1510321. Epub 2018 Aug 22. Review.


Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.

Redjal N, Zhu Y, Shah K.

Stem Cells. 2015 Jan;33(1):101-10. doi: 10.1002/stem.1834.


Glioblastoma recurrence patterns near neural stem cell regions.

Chen L, Chaichana KL, Kleinberg L, Ye X, Quinones-Hinojosa A, Redmond K.

Radiother Oncol. 2015 Aug;116(2):294-300. doi: 10.1016/j.radonc.2015.07.032. Epub 2015 Aug 11.


Influence of glioblastoma contact with the lateral ventricle on survival: a meta-analysis.

Mistry AM, Hale AT, Chambless LB, Weaver KD, Thompson RC, Ihrie RA.

J Neurooncol. 2017 Jan;131(1):125-133. doi: 10.1007/s11060-016-2278-7. Epub 2016 Sep 19. Review.

Supplemental Content

Support Center